Merriman Wealth Management’s Niagen Bioscience NAGE Stock Holding History

Merriman Wealth Management’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$62.6K	Hold	11,800	–	–	﹤0.01%	208
2024 Q3	$43.1K	Hold	11,800	–	–	﹤0.01%	215
2024 Q2	$32.2K	Buy	+11,800	New	+$39.5K	﹤0.01%	205
2024 Q1	–	Sell	-11,800	Closed	-$16.9K	–	209
2023 Q4	$16.9K	Hold	11,800	–	–	﹤0.01%	188
2023 Q3	$17.2K	Hold	11,800	–	–	﹤0.01%	189
2023 Q2	$18.5K	Hold	11,800	–	–	﹤0.01%	206
2023 Q1	$18.1K	Hold	11,800	–	–	﹤0.01%	195
2022 Q4	$19.8K	Hold	11,800	–	–	﹤0.01%	207
2022 Q3	$15K	Hold	11,800	–	–	﹤0.01%	174
2022 Q2	$20K	Hold	11,800	–	–	﹤0.01%	165
2022 Q1	$29K	Buy	+11,800	New	+$32.2K	﹤0.01%	194

Other funds holding NAGE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Merriman Wealth Management's NAGE Position: Q4 2024 in Review

Merriman Wealth Management held its Niagen Bioscience (NAGE) position steady in Q4 2024 at 11,800 shares worth $62.6K. The position accounts for ﹤0.01% of the portfolio, ranked #208.

Merriman Wealth Management first reported a position in NAGE in Q1 2022 and has held it in 11 quarters since. 123 funds tracked by Wall St. Rank hold NAGE as of Q4 2024.

Merriman Wealth Management held 11,800 shares of Niagen Bioscience worth $62.6K as of Q4 2024.
Merriman Wealth Management left its Niagen Bioscience share count unchanged in Q4 2024.
Niagen Bioscience made up ﹤0.01% of Merriman Wealth Management's portfolio in Q4 2024, its #208 holding.
Merriman Wealth Management first reported a position in Niagen Bioscience in Q1 2022 and has held it in 11 quarters since.
123 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2024.

Based on Merriman Wealth Management's 13F filing for Q4 2024, filed 13 Feb 2025.